Supriya Lifescience share news, announcements and annual reports
NSE: SUPRIYABSE: 543434Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 29 Oct 2026. Previous close ₹862.25.
29 Oct: open ₹869.25, high ₹873.55, low ₹858.05
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹6,996 Cr733rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 35.27
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 5.84
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.12%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 21.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 87,17549.0% delivered
Supriya Lifescience share news and announcements
383 announcements, routine notices left out, newest first. Page 3 of 8.
Jan 2025
24 Jan · Management
24 Jan · Board meeting
24 Jan · Results
17 Jan · Analysts
16 Jan · Board meeting
2 Jan · Analysts
2 Jan · Analysts
2 Jan
1 Jan · News Verification
The exchange asked on 1 Jan 2025
Dec 2024
30 Dec · Analysts
20 Dec · Analysts
19 Dec · Analysts
17 Dec · Analysts
11 Dec · Analysts
Nov 2024
28 Nov · Analysts
28 Nov · Analysts
13 Nov · Legal
Exchange has sought clarification from Supriya Lifescience Limited for the quarter ended 30-Sep-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.7 Nov · Analysts
6 Nov · Analysts
Oct 2024
28 Oct · Results
21 Oct · Analysts
21 Oct · Board meeting
Sep 2024
27 Sep · Meeting
18 Sep · Analysts
11 Sep · Analysts
11 Sep · Analysts
9 Sep · Analysts
5 Sep · Updates
5 Sep · Corporate action
3 Sep · Analysts
Aug 2024
29 Aug · Analysts
26 Aug · Analysts
22 Aug · Legal
Exchange has sought clarification from Supriya Lifescience Limited for the quarter ended 30-Jun-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.10 Aug · Board meeting
10 Aug · Results
5 Aug · Analysts
3 Aug · Board meeting
Jul 2024
29 Jul · Meeting
15 Jul · Analysts